Last reviewed · How we verify
sIPV batch 1
sIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3.
sIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3. Used for Prevention of poliomyelitis (poliovirus types 1, 2, and 3).
At a glance
| Generic name | sIPV batch 1 |
|---|---|
| Sponsor | Institute of Medical Biology, Chinese Academy of Medical Sciences |
| Drug class | Inactivated viral vaccine |
| Target | Poliovirus types 1, 2, and 3 |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
sIPV (Sabin inactivated poliovirus vaccine) is prepared from attenuated poliovirus strains that are chemically inactivated, making them non-infectious while retaining immunogenicity. When administered, it triggers both humoral (antibody) and cellular immune responses that protect against infection by wild-type poliovirus. This vaccine is used as part of routine immunization programs to prevent poliomyelitis.
Approved indications
- Prevention of poliomyelitis (poliovirus types 1, 2, and 3)
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |